FDA orders GLP-1 drugmakers to warn of rare eye disease
The FDA told GLP-1 drugmakers to update their product labels to reflect an increased risk of a rare eye condition that could lead to blindness. The agency said it was requiring companies to tack on ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.